Technical Analysis for MTEM - Molecular Templates, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.46 | 1.73% | 0.01 |
MTEM closed up 1.73 percent on Friday, November 1, 2024, on 1 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 11
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Narrow Range Bar | Range Contraction | 1.73% | |
Doji - Bullish? | Reversal | 1.73% | |
Wide Bands | Range Expansion | 1.73% | |
Oversold Stochastic | Weakness | 1.73% | |
NR7 | Range Contraction | 1.73% | |
Narrow Range Bar | Range Contraction | 1.73% |
Alert | Time |
---|---|
Rose Above Previous Day's High | about 17 hours ago |
Up 1% | about 20 hours ago |
Possible NR7 | 1 day ago |
Possible NR7 | 3 days ago |
Up 1% | 3 days ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is headquartered in Austin, Texas.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Solid Tumors Treatment Of Cancer Cancer Treatment Oncology Chemical Elements Lymphoma Oxygen Toxins Prodrugs Evofosfamide Prodrug Nitrogen Mustards
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Solid Tumors Treatment Of Cancer Cancer Treatment Oncology Chemical Elements Lymphoma Oxygen Toxins Prodrugs Evofosfamide Prodrug Nitrogen Mustards
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 6.25 |
52 Week Low | 0.295 |
Average Volume | 5,336,676 |
200-Day Moving Average | 1.83 |
50-Day Moving Average | 1.14 |
20-Day Moving Average | 0.78 |
10-Day Moving Average | 0.57 |
Average True Range | 0.13 |
RSI (14) | 33.33 |
ADX | 17.89 |
+DI | 28.37 |
-DI | 36.90 |
Chandelier Exit (Long, 3 ATRs) | 1.09 |
Chandelier Exit (Short, 3 ATRs) | 0.69 |
Upper Bollinger Bands | 1.61 |
Lower Bollinger Band | -0.05 |
Percent B (%b) | 0.3 |
BandWidth | 211.70 |
MACD Line | -0.22 |
MACD Signal Line | -0.20 |
MACD Histogram | -0.0172 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.47 | ||||
Resistance 3 (R3) | 0.47 | 0.47 | 0.47 | ||
Resistance 2 (R2) | 0.47 | 0.46 | 0.47 | 0.47 | |
Resistance 1 (R1) | 0.46 | 0.46 | 0.46 | 0.46 | 0.47 |
Pivot Point | 0.46 | 0.46 | 0.46 | 0.46 | 0.46 |
Support 1 (S1) | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 |
Support 2 (S2) | 0.45 | 0.45 | 0.45 | 0.45 | |
Support 3 (S3) | 0.44 | 0.45 | 0.45 | ||
Support 4 (S4) | 0.44 |